Home・Список акций・Glaukos Corp

Glaukos Corp

Закрыт

СекторЗдравоохранение

179.18 4.99

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

178.37

Макс.

180.24

Ключевые показатели
By Trading Economics
Доход	1.4M -18M
Продажи	35M 186M
Прибыль на акцию	-0.14
Рентабельность продаж	-9.901
Сотрудники	1,094
EBITDA	-11M -16M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+3.83% upside

Дивиденды
By Acuity
Следующий отчет о доходах	28 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	1.2B 10B
Предыдущая цена открытия	174.19
Предыдущая цена закрытия	179.18

Новостные настроения

By Acuity

50%

128 / 340 Рейтинг в Healthcare

Glaukos Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 авг. 2026 г., 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 авг. 2026 г., 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 июл. 2026 г., 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 июл. 2026 г., 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 июл. 2026 г., 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 июл. 2026 г., 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 июл. 2026 г., 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 июл. 2026 г., 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 июл. 2026 г., 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Сравнение c конкурентами

Изменение цены

Glaukos Corp Прогноз

Целевая цена

By TipRanks

3.83% рост

Прогноз на 12 месяцев

Средняя 186.92 USD 3.83%

Максимум 215 USD

Минимум 153 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Glaukos Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

Покупка

Удержание

Продажа

Основано на мнении 14 аналитиков, присваивавших рейтинги акциям Glaukos Corp – Данные за последние 3 месяца.

Настроения

By Acuity

128 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.